Bliss GVS Pharma announces an acquisition
TL;DR
What are the specific terms of the Share Purchase Agreement (SPA) disclosed, including the number of shares being transferred, the consideration per share, and the resulting shareholding pattern post-transaction?
The SPA transferred 5,09,84,595 Bliss GVS equity shares at Rs 299 per share, representing approximately 47.95% of the company. The SPA was signed on 23 May 2026 and completed on 28 September 2026 through Mates Visa Consultancy, Anupam Rasayan’s wholly owned subsidiary. [1]
SPA and related acquisition terms
Resulting shareholding
After combining the SPA shares, the open-offer shares and the on-market purchase, Anupam Rasayan India and Mates Visa Consultancy collectively held 5,32,36,264 shares, or 50.07% of Bliss GVS Pharma. [2]
Accordingly:
- New promoter/acquirer group: 50.07% collectively, comprising Anupam Rasayan India and Mates Visa Consultancy. [2]
- Remaining public shareholders: approximately 49.93%, derived as 100% minus the disclosed 50.07% acquirer/PAC holding.
- Promoter status: Anupam Rasayan India and Mates Visa Consultancy became the promoters, with the broader Anupam-linked entities classified as promoter group. [3]
- Former promoter group: reclassified from “Promoter and Promoter Group” to “Public” following completion of the transaction. [3]
The 50.07% figure is not the SPA stake alone; it includes the SPA acquisition, the 1,669 shares received under the open offer and the separate 22.5 lakh-share market purchase. A separate transaction summary describes the negotiated acquisition as 43.30% plus an option for a further 4.90%, but the completion disclosure reports the final SPA-related purchase as 5,09,84,595 shares. [4]
Has the change in control triggered an Open Offer under SEBI (SAST) Regulations, and if so, what is the offer price and the total number of shares proposed to be acquired from public shareholders?
Yes. The change in control triggered a mandatory Open Offer under the SEBI (SAST) Regulations.
- Offer price: Rs 299 per equity share
- Maximum shares proposed to be acquired: 2,77,26,848 equity shares
- Offer size: 26.00% of Bliss GVS Pharma’s expanded voting share capital [5]
The company subsequently disclosed that the change in control and Open Offer were completed on September 28, 2026 [3].
Which specific entities are moving from the 'Promoter' category to 'Public' (or vice versa) as part of the reclassification, and what regulatory approvals are still pending to finalize this change in the company's shareholding structure?
The reclassification is a change from the erstwhile promoter/promoter-group block to the public category, alongside the addition of a new promoter group.
Entities moving into the Public category
The latest filing states that the erstwhile Promoters and Promoter Group were reclassified as “Public” under Regulation 31A(10), but the filing excerpt does not provide a complete named list of the outgoing entities.[3]
The transaction disclosure identifies the following six sellers from the former controlling block:
- Shruti Vishal Rao
- Vibha Gagan Sharma
- Narsimha Shibroor Kamath
- Gautam Rasiklal Ashra
- Arjun Gautam Ashra
- Gulbarga Trading and Investment Private Limited
These entities sold the 43.30% stake acquired under the share-purchase agreement.[4] The six names should therefore be treated as the identified outgoing sellers; the filing excerpt does not independently map each one to the final post-transaction “Public” classification.
Entities moving into the Promoter or Promoter Group category
Promoters:
- Anupam Rasayan India Limited
- Mates Visa Consultancy Private Limited
Both acquired control and were classified as Promoters after completion of the SPA and open offer on 28 September 2026.[3]
Promoter Group:
- Kiran Pallavi Investments LLC
- Jainam Intermediates Private Limited
- ARIL Transmodal Logistic Private Limited
- ARIL Fluorospeciality Private Limited
- Anupam Japan GK
- Anupam Europe AG
- Anupam USA, LLC
- Anupam General Trading FZE
- Doriath S.A.R.L.
- Kansas HoldCo Inc.
- Kansas HoldCo 1, Inc.
- Jayhawk Fine Chemicals Corporation
- Tanfac Industries Limited
The first seven entities are listed in the updated promoter-group table in the filing.[3] The remaining six are listed in the continuation of that table.[6]
Regulatory approvals still pending
No specific pending regulatory approval is identified in the latest company disclosure. The underlying acquisition, mandatory open offer and change in control had been completed, and the Board had already taken note of the reclassification under Regulation 31A(10) on 28 September 2026.[3][3]
Accordingly, the evidence supports a completed reclassification event, not an approval still awaiting SEBI or stock-exchange clearance. Earlier transaction documentation referred generally to applicable statutory and regulatory approvals as conditions precedent, but the subsequent completion announcement indicates that those conditions had been satisfied for closing.[4]
Sources
- [1]Anupam Rasayan completes purchase of 48.2 pc stake in Bliss GVS Pharma for ₹1,750 cr - The HinduBusinessLine — The Hindu BusinessLine, 2026-09-29T00:00:00
- [2]Anupam Rasayan Acquires 22.5 Lakh Shares Of Bliss GVS Pharma For ₹162.74 Crore — Freepressjournal, 2026-09-29T00:00:00
- [3]Disclosure of Change in Control and Promoter Reclassification for Bliss GVS Pharma Limited — 2026-10-14T18:40:44.520000, p.1
- [4]Anupam Rasayan India Ltd completed the acquisition of an additional 43.30% stake in Bliss GVS Pharma Limited from Shruti Vishal Rao, Vibha Gagan Sharma, Narsimha Shibroor Kamath, Gautam Rasiklal Ashra, Arjun Gautam Ashra and Gulbarga Trading and Investment Private Limited. | MarketScreener Hong Kong — Hk, 2026-09-27T00:00:00
- [5]Bliss GVS Pharma addendum.indd — Sebi, 2026-07-17T00:00:00
- [6]Disclosure of Change in Control and Promoter Reclassification for Bliss GVS Pharma Limited — 2026-10-14T18:40:44.520000, p.2
Keep digging
